Atractylenolide III for central nervous system disorders: a review of multi-target mechanisms and therapeutic potential
Frontiers in Pharmacology · 29.05.2026 · 17
DOI: 10.3389/fphar.2026.1799976 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 29.05.2026. Verfasst von Han Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: Shenzhen Bao'an Chinese Medicine Hospital, The Seventh Clinical College of Guangzhou University of Chinese Medicine, Shenzhen, China. Die Arbeit nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Central nervous system disorders (CNSDs) are a leading cause of global mortality and disability, yet treatment options remain limited. Natural compounds derived from traditional Chinese herbs constitute a vital resource for discovering novel neuroprotective agents. Atractylenolide III (ATL-III), a sesquiterpene lactone isolated from the spleen-fortifying herb Atractylodes macrocephala Koidz., exhibits neuroprotective properties and possesses the ability to cross the blood-brain barrier (BBB). However, a systematic summary of its effects on CNSDs is currently lacking. This review therefore aimed to comprehensively summarize the therapeutic effects and underlying mechanisms of ATL-III against various CNSDs, and to provide insights for future clinical translation. A systematic literature search was conducted using PubMed, Web of Science, Google Scholar, China National Knowledge Infrastructure, and Wanfang Database for studies published or available online between 1 January 2016, and 31 December 2025. The compiled evidence demonstrates that ATL-III is effective in preclinical models of cognitive impairment, cerebral ischemia/reperfusion injury, depressive disorder, and spinal cord injury. Its neuroprotective mechanisms are multifaceted, involving the enhancement of neurotransmitter storage, reduction of neurotoxic protein accumulation, and exerting anti-apoptotic, anti-inflammatory, antioxidant, and autophagy-regulating effects, alongside BBB repair. In conclusion, ATL-III exerts broad neuroprotective effects through multi-target mechanisms, highlighting its promise as a therapeutic candidate for CNSDs. To realize this potential, key future efforts should include: (1) conducting definitive clinical trials to establish its efficacy and safety profile; (2) comprehensively elucidating its pharmacological and toxicological properties; and (3) developing novel delivery strategies to enhance its bioavailability, BBB penetration, and brain retention.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Shenzhen Bao'an Chinese Medicine Hospital, The Seventh Clinical College of Guangzhou University of Chinese Medicine, Shenzhen, China.
- Shenzhen Key Laboratory of Metabolic Health, Shenzhen Metabolism and Reproductive Targeted Delivery Proof-of-Concept Center, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China.
- Medical Research Center, Dalang Hospital of Dongguan, Dongguan, China.
Zitieren
APA
Li, H., Zeng, N. X., Ge, L., Ye, R. L., Zhuang, Y. Y., Huang, X. N., Liang, Q., Zhang, J. V., & Zhou, P. (2026). Atractylenolide III for central nervous system disorders: a review of multi-target mechanisms and therapeutic potential. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1799976
Vancouver
Li H, Zeng NX, Ge L, Ye RL, Zhuang YY, Huang XN, et al. Atractylenolide III for central nervous system disorders: a review of multi-target mechanisms and therapeutic potential. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1799976
BibTeX
@article{Li2026,
author = {Li, Han and Zeng, Ning-Xi and Ge, Lei and Ye, Rui-Liang and Zhuang, Yi-Yang and Huang, Xiao-Na and Liang, Qi and Zhang, Jian V and Zhou, Peng},
title = {Atractylenolide III for central nervous system disorders: a review of multi-target mechanisms and therapeutic potential},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1799976}
}
EUVIMED